Catalent Buys Facilities in US and Italy

Catalent Buys Facilities in US and Italy
Catalent Buys Facilities in US and Italy

Catalent Biologics, through its Paragon Gene Therapy business, has agreed to assume the leases to two Novavax facilities in Maryland, USA. The move, said Novavax, will reduce its operating costs and provide a cash payment of about $18 million, allowing the company to focus on advancing its NanoFlu and ResVax vaccines through the next phases of clinical development and regulatory review.

Stanley Erck, president and CEO of Novavax, said the “mutually beneficial” transaction allows Paragon to quickly support the growth of its gene therapy business while simultaneously offering Novavax a “strategic and cost-effective approach to addressing its manufacturing needs into the future”.

Pete Buzy, president of Paragon’s gene therapy business, added: “We look forward to working closely together in this strategic collaboration to advance Novavax’s innovative recombinant vaccines platform and expand our ability to serve the burgeoning gene and cell therapy market.”

Most of the 100 Novavax employees at the sites in Gaithersburg and Rockville will transfer to Paragon, supporting Novavax’s biologics license applications and post-licensing activities. In the longer term, Paragon will be available to manufacture commercial quantities of the vaccines for Novavax.

Concurrently, Novavax will enter into a long-term agreement with Paragon to provide process development and manufacturing services for specific Novavax programs. Both transactions are expected to complete this month.

Catalent bought Paragon for $1.2 billion in April this year, boosting its biologics capabilities.

In separate news, and in a further boost to its biologics manufacturing business, Catalent has agreed to buy Bristol-Myers Squibb’s plant in Anagni, Italy. The facility manufactures and packages oral solid, biologic and sterile products.

Catalent will continue to produce Bristol-Myers Squibb’s current product range at the site once the deal has closed, which is anticipated by the end of 2019 subject to regulatory approvals, consultation with the unions and other customary conditions.

“The addition of the Anagni facility provides our European customers with great biologics and oral dose capabilities to accelerate their development programs and improve commercial supply,” said Alessandro Maselli, Catalent’s president and chief operating officer.

The Italian plant adds to Catalent’s existing sterile fill/finish capabilities in Belgium and its drug substance, analytical and fill/finish capabilities in North America.

Virtual Event

Digitalization in the Chemical Industry
CHEManager Spotlight

Digitalization in the Chemical Industry

Save the Date: October 22, 2025
The event will be promoted to a combined audience of over 100,000 professionals across Europe through the CHEManager and CITplus networks.

Interview

Specialty Chemicals in a Shifting World
Adapting to Tariffs and Strengthening Regional Networks

Specialty Chemicals in a Shifting World

Jennifer Abril, President & CEO of SOCMA, discusses the impact of new tariffs and the importance of regional supply networks in the specialty chemical industry.

most read

Photo
13.03.2025 • News

Roche and Zealand Pharma Collaborate on Weight Management Drug

Swiss pharma heavyweight Roche announced has entered into an exclusive collaboration and licensing agreement with Denmark’s Zealand Pharma. Under the terms of this agreement, the two companies will collaborate to co-develop and co-commercialize petrelintide, Zealand Pharma’s amylin analog as a standalone therapy as well as a fixed-dose combination with Roche’s lead incretin asset CT-388.

Photo
19.03.2025 • News

Arkema Launches Acrylic Acid Purification Project

Arkema has announced the launch of its Carat Project at its Carling site in France. This initiative aims to enhance the capabilities and sustainability of the facility, which specializes in producing acrylic monomers and superabsorbent polymers.